Kintara Therapeutics Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
- Financing Rounds
-
12
- Investments
-
3
Kintara Therapeutics General Information
Description
Provider of cancer therapies intended to treat common and aggressive forms of cancer in the human body. The company's platform provides novel cancer therapies, two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced-risk development programs for patients with unmet medical needs
Contact Information
Website
www.kintara.comCorporate Office
- 9920 Pacific Heights Boulevard
- Suite 150
- San Diego, CA 92121
- United States
Corporate Office
- 9920 Pacific Heights Boulevard
- Suite 150
- San Diego, CA 92121
- United States
Kintara Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kintara Therapeutics Comparisons
Industry
Financing
Details
Kintara Therapeutics Competitors (31)
One of Kintara Therapeutics’s 31 competitors is Peloton Therapeutics, a Formerly VC-backed company based in Dallas, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Peloton Therapeutics | Formerly VC-backed | Dallas, TX | ||||
| BeiGene | Formerly PE-Backed | Beijing, China | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA |
Kintara Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kintara Therapeutics Patents
Kintara Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220226277-A1 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | Active | 01-Dec-2017 | ||
| US-11717505-B2 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | Active | 01-Dec-2017 | ||
| US-20230338325-A1 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | Pending | 01-Dec-2017 | ||
| US-20200062839-A1 | Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer | Inactive | 01-May-2017 | ||
| US-20200061054-A1 | Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor | Inactive | 28-Feb-2017 | A61P35/00 |
Kintara Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kintara Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kintara Therapeutics Acquisitions (3)
Kintara Therapeutics’s most recent deal was a Reverse Merger with TuHURA Biosciences. The deal was made on 03-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TuHURA Biosciences | 03-Apr-2024 | Reverse Merger | Drug Discovery | ||
| Adgero Biopharmaceuticals | 19-Aug-2020 | Merger/Acquisition | Biotechnology | ||
| Berry Only | 25-Jan-2013 | Merger/Acquisition | Holding Companies |
Kintara Therapeutics FAQs
-
When was Kintara Therapeutics founded?
Kintara Therapeutics was founded in 2009.
-
Where is Kintara Therapeutics headquartered?
Kintara Therapeutics is headquartered in San Diego, CA.
-
What is the size of Kintara Therapeutics?
Kintara Therapeutics has 2 total employees.
-
What industry is Kintara Therapeutics in?
Kintara Therapeutics’s primary industry is Drug Discovery.
-
Is Kintara Therapeutics a private or public company?
Kintara Therapeutics is a Private company.
-
What is Kintara Therapeutics’s current revenue?
The current revenue for Kintara Therapeutics is .
-
How much funding has Kintara Therapeutics raised over time?
Kintara Therapeutics has raised $93M.
-
Who are Kintara Therapeutics’s investors?
Berry Only has invested in Kintara Therapeutics.
-
Who are Kintara Therapeutics’s competitors?
Peloton Therapeutics, BeiGene, Novartis, Poseida Therapeutics, and Blueprint Medicines are some of the 31 competitors of Kintara Therapeutics.
-
When was Kintara Therapeutics acquired?
Kintara Therapeutics was acquired on 17-Oct-2024.
-
Who acquired Kintara Therapeutics?
Kintara Therapeutics was acquired by TuHURA Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
